Sharemaestro Newsreel

TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating

TD Cowen has reiterated its Buy rating on Century Therapeutics (IPSC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.

Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …

Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71

Stifel has reiterated its Buy rating for UniQure NV (QURE.US), maintaining its target price at $71. This indicates continued confidence from Stifel in the company's stock performance.

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Akari Therapeutics Q2 Results: Net loss widens to $4.8 million

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026, widening from $1.9 million year-over-year, primarily due to increased R&D expenses as it advances its lead ADC candidate, AKTX-101, towards mid-2027 Phase 1 trials. The company strengthened its financial position by raising …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

DRTS Forecast — Price Target — Prediction for 2027

Stocks See Support from Favorable PPI Report

The S&P 500 Index ($SPX) (SPY) is up +0.57%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%. September E-mini S&P futures (ESU26) are up +0.58%, and September E-mini Nasdaq futures (NQU26) are …

Omeros (OMER) Stock Jumps On YARTEMLEA Profit Breakthrough

Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump

Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock

Korro Bio (NASDAQ:KRRO) director Jean Francois Formela sold 2,143 shares of the company's stock for $29,916.28 on August 11th, reducing his holdings by 1.45% to 145,937 shares. This sale is part of a pattern of recent insider selling by Formela, including significant transactions in …

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …

Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22

Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action date of August 22,” and framed updates around “our …

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap …

Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com

This article announces that Ovid Therapeutics Inc. filed a Form 8K on August 13. The brief notice from Investing.com indicates that the filing is available for review, with the company's stock symbol OVID mentioned alongside a slight positive change.

NovaBridge Biosciences to report H1FY26 results on Aug 20

NovaBridge Biosciences (NASDAQ: NBP) will hold a webcast on August 20, 2026, to discuss its financial results for the first half ended June 30, 2026, and provide a corporate update. The company, focused on oncology and ophthalmology programs, will host the webcast at 9:00 …

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Yarrow Bioscience announced its second quarter 2026 financial results, highlighting progress in its Phase 2a/2b clinical trial for YB-101, an anti-TSHR antibody for Graves’ disease and thyroid eye disease. The company completed a reverse merger with VYNE Therapeutics and private financings totaling $200 million, …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct

Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling …

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

Bio-Techne (TECH) Stock Stalls As 61.8x P E Meets Soft Demand

CELCUITY ($CELC) Releases Q2 2026 Earnings

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) reported a Q2 loss of $0.22 per share, outperforming the Zacks Consensus Estimate of a $0.24 loss. The company's revenues for the quarter ended June 2026 reached $1.78 million, surpassing estimates by 31.78%. Despite beating earnings and revenue expectations, CAMP …

Seer (SEER) Stock Faces Revenue Slump As Losses Stay Heavy

Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise

Omeros Corporation reported a swing to profit in Q2 2026, driven by significant revenue growth from its YARTEMLEA sales. The company also announced plans to initiate two new studies for YARTEMLEA by the end of 2026, targeting hyperinflammatory acute respiratory distress syndrome (ARDS) and …

Halozyme (HALO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Tram Bui President and Chief Executive Officer - Dr. Helen Torley Chief Financial Officer - Darren Snellgrove Full Conference Call Transcript Operator: …

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

Zai Lab Director William Lis Executes Sale of 8,506 ADS Shares Under Rule 10b5-1 Plan

William Lis, a director at Zai Lab Ltd (NASDAQ:ZLAB), sold 8,506 American Depositary Shares (ADS) on August 12, 2026, for $25 per ADS. This transaction was conducted as per a pre-established Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Lis directly …

Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges

Eledon Pharmaceuticals' Q2 2026 Form 10-Q filing reveals significant concerns about its ability to continue as a going concern due to ongoing operating losses and the critical need for additional financing. The company anticipates continued losses and warns that failure to secure more capital …

Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4

Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.

X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award

John Volpone, President of X4 Pharmaceuticals (NASDAQ: XFOR), sold 24,576 shares of company stock on August 12, 2026. This transaction was executed to cover personal income tax liabilities associated with the settlement of a restricted stock unit (RSU) award. Following the sale, Volpone beneficially …